The National Methamphetamine
Drug Conference

Conference Proceedings

Table of Contents

Acknowledgments

Conference Summary

Conference Presentations

1. Opening Remarks
   • Director Barry R. McCaffrey
   • U.S. Senator J. Robert Kerrey
   • Governor E. Benjamin Nelson

2. Plenary Presentations
   • History—David Musto, M.D., Yale University
   • Treatment—Alan Leshner, Ph.D., National Institute on Drug Abuse
   • Data—Jeremy Travis, J.D., National Institute of Justice
   • Intelligence—Randy Weaver, National Drug Intelligence Center
   • National Drug Strategy—James McDonough, ONDCP

3. Keynote Addresses
   • Janet Reno, J.D., United States Attorney General
   • Thomas Constantine, Drug Enforcement Administration

4. Workgroup Summary Reports
   • Prevention—Leslie Bloom, Partnership for a Drug-Free America and Martha Gagné, American Council for Drug Education
   • Education—Kenneth Bird, Ph.D., Westside Schools Superintendent
   • Treatment—Everett Ellinwood, M.D., Duke University Medical Center
   • Clandestine Labs—Luke Galant, DOJ—Bureau of Justice Assistance
   • Drug Courts—The Honorable Richard Shull, J.D., Wichita, Kansas, and Anne Camp, U.S. Attorney's Office for Nebraska
   • Precursor Chemical Control—Laura Birkmeyer, J.D., Assistant U.S. Attorney

5. Medical Panel Discussion—Perspectives from Physicians
   • Hoover Adger, M.D., ONDCP Deputy Director, Moderator
   • Everett Ellinwood, M.D., Duke University Medical Center
   • Tom Leland, M.D., Community Care Services, Honolulu, Hawaii
   • Scott Lukas, Ph.D., Harvard Medical School
   • Richard Rawson, Ph.D., the Matrix Institute, Los Angeles, California
   • Michael Sise, M.D., Mercy Hospital, San Diego, California

6. Closing Remarks
   • U.S. Senator J. Robert Kerrey
   • Director Barry R. McCaffrey

Appendices

Conference Agenda

Workgroup Briefings (in order of presentation)

Workgroup 1: Prevention

• Gabriel Georges Nahas, M.D., Ph.D., New York University Medical Center
• Eve Bachrach, J.D., Nonprescription Drug Manufacturers Association
• Jim Kielley, Warner-Lambert
• Leslie Bloom, Partnership for a Drug-Free America
• David Hatcher, Hatcher and Associates
• Discussion

Workgroup 2: Education

• David Walker, North Carolina Partnership for Children
• William Alden, D.A.R.E. America
• Dick Palmquist and Karen Walklin, Nebraska Broadcasters Association
• Cathy Siders, Ph.D., Psychologist
• Discussion

Workgroup 3: Treatment

• Michael Sise, M.D., Mercy Hospital
• Richard Rawson, Ph.D., The Matrix Institute
• Rebecca Games, Games and Associates
• Discussion

Workgroup 4: Clandestine Labs

• George J. Doane, California Bureau of Narcotic Enforcement
• Scott Lukas, Ph.D., Harvard Medical School
• Karl Palmer, California Department of Toxic Substance Control
• Terry Brubaker, U.S. Environmental Protection Agency, Region 9
• Discussion

Workgroup 5: Drug Courts

• Judge Richard Shull, Municipal Court, Wichita, Kansas
• Tom Leland, M.D., Community Care Services
• Alice Huber, Ph.D., the Matrix Institute
• Judge James Livingston, District Judge, Grand Island, Nebraska
• Larry Ferrell, J.D., Assistant U.S. Attorney, Missouri
• Discussion

Workgroup 6: Precursor Chemical Control

• Walter Ling, M.D., The Matrix Institute
• Harry Matz, J.D., U.S. Department of Justice
• Edward Machado, California Bureau of Narcotic Enforcement
• William Wolf, U.S. Drug Enforcement Administration
• Discussion

Program Committee